Abstract
All renal allograft recipients (n = 32) in Sweden and Norway who were converted from cyclosporin(CyA)-based immunosuppression to FK 506 (tacrolimus) between October 1992 and June 1995 were analyzed retrospectively. The reasons for conversion were acute refractory rejection (n = 21), chronic rejection (n = 4), and suspected CyA toxicity (n = 6); one patient was converted for psychological reasons. The mean time from transplantation to conversion was 29 (range 1–243) weeks and there was a mean follow-up of 46 (2–143) weeks. Overall graft survival was 59%, with graft survival 52% in patients converted because of acute rejection, 50% in patients converted because of chronic rejection, and 83% in patients converted because of CyA toxicity. There was no significant correlation between preconversion serum creatinine and outcome. Seventy-two percent of the patients had significant side effects during FK 506 treatment, the most frequent ones being neurological and gastrointestinal symptoms. These improved after dose reduction. Two patients became overimmunosuppressed and developed lymphoma. One patient died of the primary kidney disease, hemolytic uraemic syndrome. We conclude that FK 506 therapy is able to salvage kidneys with acute refractory rejection and that it is an alternative in patients with CyA toxicity. However, the risk of overimmunosuppression must be considered.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Almond PS, Gillingham KJ, Sibley R, Moss A, Melin M, Leventhal J, Manivel C, Kyriakides P, Payne WD, Dunn DL, Sutherland DER, Gores PF, Najarian JS, Matas AJ (1992) Renal transplant function after 10 years of cyclosporine. Transplantation 53: 316–323
Bäckman L, Nicar M, Levy M, Distant D, Eisenstein C, Renard T, Goldstein R, Husberg B, Gonwa TA, Klintmalm G (1994) FK506 trough levels in whole blood and plasma in liver transplant recipients. Transplantation 57: 519–525
European FK506 Multicenter Liver Study Group (1994) Randomised trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet 344: 423–428
Grenier FC, Luczkiw J, Bergmann M, Lunetta S, Morrison M, Blonski D, Shoemaker K, Kobayashi M (1991) A whole blood FK 506 assay for the IMx® analyzer. Transplant Proc 25: 2748–2749
Japanese FK 506 Study Group (1993) Japanese study of FK506 on kidney transplantation: results of late phase II study. Transplant Proc 25: 649–654
Jordan M, Shapiro R, Vivas CA, Scantlebury VP, Rhanhawa P, Carrieri G, McCauley J, Demetris AJ, Tzakis A, Fung JJ, Simmons RL, Hakala TR, Starzl TE (1994) FK 506 “rescue” for resistant rejection of renal allografts under primary cyclosporine immunesuppression. Transplantation 57: 860–865
Lu CY, Sicher SC, Vazquez MA (1993) Prevention and treatment of renal allograft rejection: new therapeutic approaches and new insights into established therapies. J Am Soc Nephrol 4: 1239–1256
Shapiro R, Jordan M, Scantlebury V, Fung J, Jensen C, Tzakis A, McCauley J, Carroll P, Riccordi C, Demetris AJ, Mitchell S, Jain A, Iwaki Y, Kobayashi M, Reyes J, Todo S, Hakala TR, Simmons RL, Starzl TE (1991) FK 506 in clinical kidney transplantation. Transplant Proc 23:3065–3067
Solez K, Axelsen RA, Benediktsson H, Burdick JF, Cohen AH, Colvin RB, Croker BP, Droz D, Dunhill MS, Halloran PF, Häyry P, Jennette JC, Keown PA, Marcussen N, Mihatsch MJ, Morozumi K, Myers BD, Nast CC, Olsen S, Racusen LC, Ramos LE, Rosen S, Sachs DH, Salomon DR, Sanfilippo F, Verani R, Willebrand E von, Yamaguchi Y (1993) International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 44: 411–422
US Multicenter FK 506 Liver Study Group (1994) A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 331: 1110–1115
Author information
Authors and Affiliations
About this article
Cite this article
Felldin, M., Bäckman, L., Brattström, C. et al. Rescue therapy with tacrolimus (FK 506) in renal transplant recipients —a Scandinavian multicenter analysis. Transplant Int 10, 13–18 (1996). https://doi.org/10.1007/BF02044336
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02044336